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Alkylating agents have been shown to be very promising for the radiolabelling of oligonucleotides with
ﬂuorine-18. In this report we describe the fully automated synthesis of 2-bromo-N-[3-(2-[18F]ﬂuor-
opyridin-3-yloxy)propyl]acetamide ([18F]FPyBrA) utilizing a modular synthesis unit. Reaction condi-
tions for the coupling of this pyridine-based alkylating agent at the 50 end of a fully phosphorothioated
random 20-mer DNA sequence were optimized to achieve very high radiochemical yields (490%) and a
maximum speciﬁc activity of 5–6GBq/mmoL. The potential for rapid puriﬁcation by solid phase
extraction without need of chromatographic isolation of the radiolabelled oligonucleotide presents an
overall beneﬁt for the application of oligonucleotides in preclinical studies and potential clinical
applications.
& 2009 Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Oligonucleotides (ODN), formulated as antisense ODN (Tamm
et al., 2001; Hnatowich, 1999) and aptamers (Brody and Gold,
2000; Perkins and Missailidis, 2007), are very attractive candi-
dates for developing new therapeutic drugs or imaging agents.
The antisense technology is based on the speciﬁc hybridization of
an antisense ODN to its complementary target mRNA, whereas
aptamers are ODN designed to bind speciﬁcally and with high
afﬁnity to a variety of target molecules. ODN can be easily
synthesized and the development of the systematic evolution of
ligands by exponential enrichment (selex) has accelerated the
isolation of ODN sequences capable of recognizing virtually any
class of target molecules (Ellington and Szostak, 1990; Tuerk and
Gold, 1990). The excellent targeting capacities of ODN make them
ideal agents for molecular imaging purposes (Tavitian, 2003),
recognizing that there are still many improvements needed for
their safe and effective application in vivo (Younes et al., 2002).
Various labelling strategies for the synthesis of ODN-based
molecular imaging agents have been described for positron+17809898483.
Mercer).
uclear Medicine, Innsbruck
Austria.
Y-NC-ND license.emission tomography (PET) (Dolle´ et al., 1997; Yngve et al.,
1999; Hedberg and Langstrom, 1997, 1998; Kuhnast et al., 2000,
2003, 2004; de Vries et al., 2003), single-photon emission
tomography (Hjelstuen et al., 1998; Hicke et al., 2006), magnetic
resonance imaging (Paunesku et al., 2008), and reﬂectance-based
molecular imaging (Javier et al., 2008). Within the spectrum of
non-invasive molecular imaging techniques, PET provides the
highest sensitivity and the best capacity for quantitative mea-
surements of physiological processes in vivo at the cellular
and molecular level. The short-lived positron emitter ﬂuorine-18
(18F) is a particularly attractive radionuclide for the design and
synthesis of PET-radiotracer due to its favourable nuclear proper-
ties, high reactivity of the no carrier added [18F]ﬂuoride ion
produced by irradiation of 18O-enriched water, and availability of
large radioactivity quantities from medical cyclotrons. The low
positron energy of 0.64MeV results in low radiation doses and
short tissue range, and the relatively long 109.7min half-life
allows complex and multi-step radiosyntheses and imaging
protocols of 4–6h. However, radiolabelling of biomolecules with
18F presents speciﬁc challenges. Direct incorporation of 18F at high
speciﬁc radioactivity into biomolecules such as peptides, proteins
and ODN is hampered by the harsh reaction conditions occurring
during labelling reactions. In order to circumvent this obstacle,
18F-labelling of biomolecules including ODN is usually carried out
by means of prosthetic groups, also referred to as bifunctional
labelling agents (Wester and Schottelius, 2007). Compared to the
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Fig. 1. A selection of prosthetic groups used for ODN-labelling with 18F.
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labelling of amino acid-based biomolecules like peptides and
proteins, only a few prosthetic groups have been used for labelling
ODN. The incorporation of 18F into ODN was accomplished via
acylation (Hedberg and Langstrom, 1998), alkylation (Dolle` et al.,
1997; Kuhnast et al., 2000, 2003, 2004; de Vries et al., 2003),
photochemical conjugation (Lange et al., 2002), and thiourea
formation (Hedberg and Langstrom, 1997). Acylation, photochemical
conjugation and thiourea formation are based on the presence of a
primary amine group-containing alkyl chain linked to the 50 position
of the ODN, whereas alkylation reactions rely on the reaction with a
phosphorothioate group at the 30 or 50 end of the ODN backbone.
Fig. 1 displays some of the prosthetic groups which have been
used for ODN-labelling with 18F; including N-succinimidyl
4-[18F]ﬂuorobenzoate ([18F]SFB), 4-([18F]ﬂuoromethyl)phenyl isothio-
cyanate ([18F]FMPI), 3-azido-5-nitrobenzyl-[18F]ﬂuoride ([18F]ANBF),
N-(4-[18F]ﬂuorobenzyl)-2-bromoacetamide ([18F]FBBA) and 2-bromo-
N-[3-(2-[18F]ﬂuoropyridin-3-yloxy)propyl]acetamide ([18F]FPyBrA).
Conjugation of the prosthetic groups [18F]SFB (acylation),
[18F]FMPI (thiourea formation) and [18F]ANBF (photochemistry)
to ODN (15-mer, 18-mer and 20-mer) containing a hexylamine
linker afforded only low to moderate radiochemical yields (RCY)
in the range of 7–23% (Hedberg and Langstrom, 1997, 1998; Lange
et al., 2002). Signiﬁcantly improved RCY could be achieved by
exploiting the alkylation reactions of ODN (9-mer and 18-mer)
containing a phosphorothioate moiety with [18F]FBBA and
[18F]FPyBrA, respectively. The conjugation reaction proceeded
rapidly under mild conditions in RCY of 45–75% (Kuhnast
et al., 2000, 2004). The advantage of alkylation reaction for
ODN-labelling was further conﬁrmed by a comparative study
of various alkylating agents in a model reaction with adenosine
50-O-thiomonophosphate (de Vries et al., 2003).
In this report we describe the automated modular synthesis of
[18F]FPyBrA based on the robotic synthesis described by Kuhnast
et al. (2004) using a commercially available modular synthesis
unit. We further describe optimization strategies for the conjuga-
tion of this alkylating agent to the 50 terminus of an ODN, using a
fully phosphorothioated random 20-mer ODN as a model.
Reaction conditions were optimized to achieve high radiolabelling
yields with a minimum amount of ODN, obtaining the radio-
labelled agent at high speciﬁc activity and without need of
puriﬁcation.2. Materials and methods
2.1. General
All chemicals obtained commercially were of analytic or HPLC
grade and were used without further puriﬁcation unless other-
wise stated.The N-Boc-protected nitro-precursor, [3-(2-nitropyridin-
3-yloxy)propyl] carbamic acid tert-butyl ester (1) was synthesized
according to Kuhnast et al. (2004). The non-radioactive, ﬂuori-
nated reference compound 2-bromo-N-[3-(2-[19F]ﬂuoropyridin-
3-yloxy)propyl]acetamide ([19F]FPyBrA) was kindly provided by
Fre´de´ric Dolle´ (Service Hospitalier Fre´de´ric Joliot, Institut d’Ima-
gerie Biome´dicale — CEA, Orsay, France). [18F]ﬂuoride was
produced on a TR-19/9 cyclotron (Advanced Cyclotron Systems,
Burnaby, Canada) by the 18O (p, n)18F nuclear reaction.
A 20-mer oligodeoxynucleotide with phosphorothioate back-
bone and a phosphorothioate monoester at the 50 end (PS-ODN)
with the sequence 50-CCG-GTG-AAC-GAG-CGA-GCA-CA-30 (Tian
et al., 2000) and purity 490% as analyzed by high performance
liquid chromatography and mass spectrometry was purchased
from the University Core DNA Services (Calgary, Canada) and used
to evaluate the radiolabelling performance of [18F]FPyBrA.
2.2. Analytical methods
Thin layer chromatography (TLC). Radio-TLC (MK6F Silica Gel
60 A˚, size 2.57.5 cm, layer thickness 250mm, Whatman, Maid-
stone, UK) with ethyl acetate (EtOAc) was used to monitor the RCY
of the different reaction steps during the optimization of the
automated synthesis. The radioactivity distribution on the plate
was analyzed with a TLC-scanner (Mini-Scan, Bioscan, Washing-
ton DC, USA) and the retention factor (Rf) was calculated. All
compounds were additionally localized with UV illumination at
254nm. The ﬁnal radiochemical purity (RCP) of [18F]FPyBrA after
puriﬁcation was analyzed by radio-TLC co-spotted with the non-
radioactive ﬂuorinated reference compound (Rf 0.7). The decay-
corrected and non-decay-corrected RCY was calculated based on
starting [18F]ﬂuoride.
High performance liquid chromatography (HPLC). [18F]FPyBrA
([18F]-4) was puriﬁed by normal phase HPLC on a Knaur
chromatography system (Berlin, Germany), equipped with a
Waters Prep Nova-Paks HR Silica column (Semi/Prep;
3007.8mm; porosity 6mm), integrated radioactivity detection
and UV detection at 254nm (ﬁxed wavelength detector K-200,
Knaur, Berlin, Germany), using isocratic elution with dichloro-
methane (CH2Cl2)/EtOAc (1/1, v/v) and ﬂow rate 5mL/min (HPLC
method 1). The radioactive peak corresponding to [18F]-4 with
retention time (Rt) 5min was collected by remote control. The RCP
of [18F]-4 and the radiolabelled PS-ODN was analyzed by reversed
phase HPLC on a Beckman Coulter chromatography system with a
Model 126 analytical dual pump, Model 168 Diode Array variable
UV detector and ACE MateTM Single Channel Analyzer (Ortec, TN)
radiometric detection, equipped with a Phenomenex Luna C18
column (Semi/Prep; 25010.0mm; porosity 10mm) using a
gradient system of 0.1M aqueous triethylammonium acetate
pH 7 and acetonitrile (ACN) with ﬂow rate 3mL/min and
increasing concentrations of ACN: 0–20min 10–50%, 20–21min
50–70%, 21–25min 70%, 25–26min 70–10%, 26–30min 10% (HPLC
method 2).
Ultraviolet–visible (UV) spectroscopy. The concentration of ODN
was determined by UV spectroscopy at 260nm using a Beckman
DU 7400 spectrophotometer.
2.3. Automated radiosynthesis of [18F]FPyBrA
A commercially available modular synthesis system (Modular
Lab, Eckert & Ziegler, Berlin, Germany) was used for the fully
automated radiosynthesis. The modular system included two
reactor modules, a variety of valve modules, a vacuum pump and a
compact HPLC module (K-120, Knaur, Berlin, Germany) and was
PC controlled through the programming of the Modular-Lab
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Scheme 1. Schematic diagram of the automated synthesis set-up for [18F]FPyBrA production.
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Scheme 1.
The radiosynthesis of [18F]FPyBrA according to Kuhnast et al.
(2004) was carried out in three synthesis steps (see Fig. 2):
(1) introduction of 18F into the pyridine ring by nucleophilic
heteroaromatic substitution, (2) removal of the N-Boc protective
group and (3) amide formation with 2-bromoacetyl bromide. Each
synthesis step was evaluated and optimized over 60 separate
preparations as described in the following sections:
Synthesis of [3-(2-[18F]ﬂuoropyridin-3-yloxy)propyl] carbamic acid
tert-butyl ester ([18F]-2). Aqueous [18F]ﬂuoride was introduced into
the synthesis unit by applying a nitrogen stream and trapped on an
anion-exchange resin (Sep-Paks Light QMA cartridge, Waters,
Milford, MA), preconditioned with 10mL of 0.5M potassiumcarbonate (K2CO3) and 20mL of water. The target [
18O]H2O was
recovered and [18F]ﬂuoride was eluted into reactor one using a
0.8mL mixture of 2.1mg/mL K2CO3 in water and 11.8mg/mL
4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (Kryptoﬁx
222) in ACN (15/85, v/v). The resulting solution was concentrated
to dryness under reduced pressure and nitrogen stream at
85–100 1C to obtain the no carrier added K[18F]-K222 complex.
The temperature was reduced to 50 1C and 5mg of 1 in 0.6mL
anhydrous dimethylsulfoxide (DMSO) was added and allowed to
react with the K[18F]-K222 complex at 150 1C for 4min with
stirring (silica gel TLC, eluent EtOAc, Rf 0.9). The temperature was
reduced again to 50 1C and the reaction mixture was diluted with
5mL of water and transferred onto a C-18 cartridge (Sep-Paks
C-18 Plus, Waters, Milford, MA), preconditioned with 5mL of
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additional portion of 5mL water to separate unreacted [18F]ﬂuor-
ide and the C-18 cartridge was partially dried by applying a
nitrogen stream for 30 s to minimize residual moisture. [18F]-2
was eluted into reactor two with 3.5mL of CH2Cl2.
Synthesis of 3-(2-[18F]ﬂuoropyridin-3-yloxy)propylamine ([18F]-3).
Triﬂuoroacetic acid (TFA; 100mL in 0.5mL CH2Cl2) was added to
reactor two to carry out N-Boc deprotection and the solvent was
evaporated at 75 1C for 5min (silica gel TLC, eluent EtOAc, Rf 0.0).
After evaporation of the solvents an additional drying step with
1mL ACN at 85 1C for 2.5min under reduced pressure and nitrogen
stream was performed to reduce the TFA content and residual
moisture. Before continuing with the last reaction step reactor two
was cooled to 37 1C.
Synthesis of [18F]FPyBrA ([18F]-4). The residue containing [18F]-3
was redissolved with 40mL triethylamine (TEA) in 0.5mL CH2Cl2
followed by addition of 20mL of 2-bromoacetyl bromide
(BrCOCH2Br) in 0.5mL CH2Cl2. The reaction mixture was reacted
for 3min at 37 1C to obtain the ﬁnal product (silica gel TLC, eluent
EtOAc, Rf 0.7). For puriﬁcation on normal phase HPLC the ﬁnal
reaction mixture was diluted with 1mL CH2Cl2/EtOAc (1/1, v/v)
and passed through a GHP Acrodiscs GF 25mm, 0.45mm ﬁlter
(Waters, Milford, MA) before injection into the HPLC system.
Online normal phase HPLC puriﬁcation was performed with
a Knaur HPLC-module (Berlin, Germany) using HPLC method 1
(Rt 5min). The whole synthesis including puriﬁcation was
performed within 65min affording pure [18F]-4 in 5mL HPLC
solvent. The solvents were evaporated and [18F]-4 was redissolved
in a minimum amount of methanol (MeOH).Table 1
Reagent list for the automated radiosynthesis of [18F]FPyBrA (Scheme 1).
Filling of the synthesis unit
1–2mL aqueous [18F]ﬂuoride
0.8mL K222/K2CO3 mixture
5mg nitro-precursor in 0.6mL DMSO
10mL water for dilution and washing steps
3.5mL CH2Cl2 for SepPak elution
0.5mL CH2Cl2 containing 100mL TFA
1mL ACN to minimize TFA content
0.5mL CH2Cl2 containing 40mL TEA
0.5mL CH2Cl2 containing 20mL BrCOCH2Br
1mL HPLC eluent2.4. Oligonucleotide labelling
The PS-ODN dissolved in 0.1M phosphate buffered saline (PBS)
pH 7 at a concentration of 1mg/mL was conjugated with [18F]-4 in
varying concentrations of PBS/MeOH at 120 1C for 15–30min in a
sealed V-vial. The inﬂuence of the pH, MeOH concentration and
PS-ODN concentration on the radiolabelling performance was
evaluated.
The RCP of the different reaction mixtures was analyzed by
HPLC method 2. The overall recovery of labelled ODN from the
HPLC system was monitored and the formation of radiocolloids
was analyzed by solid phase extraction on a Sep-Paks C-18 Light
cartridge (Waters, Milford, MA). The concentration of PS-ODN was
conﬁrmed by UV spectroscopy at 260nm before and after
radiolabelling.Table 2
Overview of the radiolabelling performance in the synthesis of [18F]FPyBrA.
Radiolabelling performance Min Max Mean7sd (n)
Nitro-precursor (mg) 3.6 9.1 5.971.2 (60)
Starting [18F]ﬂuoride (MBq) 85 4212 78071021 (60)
Activity in reactor one (%)a 50 100 81710 (40)
Activity in reactor two (%)a 21 51 3879 (40)
Activity in the waste (%)a 22 48 3477 (40)
Unrecovered activity on the QMA catridge (%)a 1 4 271 (20)
Unrecovered activity on the SepPak catridge (%)a 1 10 472 (40)
Yield of nucleophilic substitution (% RCY)b 48 89 74711 (40)
Yield of N-Boc-deprotection (% RCY)b 88 100 9674 (20)
Yield of bromoacetylation (% RCY)b 31 78 63710 (20)
Activity recovery during HPLC puriﬁcation 60 87 7377 (10)
Decay-corrected yielda 11 24 1775 (10)
Non-decay-corrected yield 7 16 1173 (10)
a Decay-corrected based on starting [18F]ﬂuoride.
b According to TLC.3. Results and discussion
The preparation of 18F-labelled imaging probes is a complex
process often involving multiple reaction steps requiring puriﬁca-
tion of the intermediates and the ﬁnal product and is more easily
accomplished in automated synthesis units (Satyamurthy et al.,
1999). The commercially available synthesis units, however, are
generally designed for the optimized preparation of a speciﬁc
radiopharmaceutical, most prominently 2-[18F]ﬂuoro-2-deoxy-D-
glucose ([18F]FDG). There are several reports on performing a
variety of other one-pot labelling strategies in commercially
available FDG modules (Reischl et al., 2005; Hamacher and
Coenen, 2002; Ryzhikov et al., 2005; Oh et al., 2005; Kryza et
al., 2008). We have recently described the automated radio-
synthesis of [18F]FBBA in a TRACERLab FXFDG system (GE Medical
Systems) (Koslowsky et al., 2008). The development of novel
multistage synthesis procedures for 18F-labelled radiotracers
within these systems is not always possible or is complicated bythe requirement for extensive software and hardware modiﬁca-
tions (Marik and Sutcliffe, 2007).
Recently several modular automated radiosynthesis units have
become available. These units can be conﬁgured to permit user-
designed, multi-step reactions to be performed (Krasikova, 2007).
In this study we used such a modular system for the fully
automated radiosynthesis and remote-controlled semi-prepara-
tive HPLC puriﬁcation of [18F]FPyBrA. The synthesis unit was
readily conﬁgured for the three-step synthesis according to
Kuhnast et al. (2004) starting from the nitro-precursor (see
Scheme 1 and Fig. 2). The PC-controlled synthesis was optimized
during the initial synthesis evaluation by programming of the
controlling software. Minor modiﬁcations of the synthesis
allowed improvements of the RCY in each reaction step. The
reagents loaded into the system for the optimized synthesis of
[18F]FPyBrA are presented in Table 1.
During the optimization of the automated synthesis a total of
60 batches of [18F]FPyBrA were produced. An overview of the
radiolabelling performance is given in Table 2. [18F]ﬂuoride was
efﬁciently desorbed (X94%) from the QMA cartridge using a 2:1
molar ratio of K222 and K2CO3 as recommended previously
(Gomzina et al., 2002) in 0.8mL of solvent. A single drying
sequence without additional azeotropic drying steps with ACN
proved effective. The average precursor amount of 5.9mg
(20mmol) resulted in an almost equimolar K222 to 1 ratio. This
ratio together with a slightly increased reaction temperature of
150 1C (Tewson and Watkins, 2001) resulted in an optimized yield
as determined by TLC. The presence of undissolved K[18F]-K222
complex (Block et al., 1986) was noted in some reactions resulting
in lower yields. This loss was reduced by stirring the contents
during the ﬁrst reaction step.
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after elution of [18F]-2 from the C-18 cartridge due to unavoidable
losses during transfer although no activity losses due to wall
absorption on the reaction vessel were observed (Block et al.,
1987). Activity loss due to retention of [18F]-2 on the cartridge was
reduced by incubating the cartridge with CH2Cl2 for 30 s before
continuing the elution into reactor two. Despite drying of the C-18
cartridge prior to CH2Cl2 elution by applying a nitrogen stream for
up to 5min, residual moisture was always present in the eluate.
As already described by Schildan et al. (2007) no deprotection
was achieved by addition of TFA and reaction at room tempera-
ture, whereas heating at moderate temperatures of 50–60 1C
resulted in N-Boc-deprotection of greater than 80% and evapora-
tion of the solvents at 75 1C under reduced pressure and nitrogen
stream resulted in virtually quantitative deprotection (495%) as
determined by TLC. Residual moisture and TFA were successfully
removed by an additional drying step with ACN at 85 1C. No
signiﬁcant losses of radioactivity were observed in this step of the
synthesis.
The reaction between the intermediate propylamine ([18F]-3)
and BrCOCH2Br proceeded readily to form [
18F]FPyBrA ([18F]-4)
with optimized labelling yields obtained at room temperature
after 3min with TEA concentration being a signiﬁcant determi-
nant of RCY (430% with 20mL TEA; 460% with 40mL TEA).
A similar improvement was reported also by Viel et al. (2007).
HPLC puriﬁcation of the crude product resulted in a mean
recovery of 73% of pure [18F]-4.
For the complete three step reaction to form [18F]-4 under
optimized radiolabelling conditions, a maximum overall decay-
corrected RCY of 24% based on starting [18F]ﬂuoride, correspond-
ing to a non-decay-corrected RCY of 16% was achieved with a
65min synthesis time.
The ﬁnal phase of this study involved the coupling of the
18F-labelled prosthetic group ([18F]-4) at the 50 end of a model 20-
mer PS-ODN. The reaction was optimized to a very high yield
(490%) by adjusting the reaction parameters of temperature
(120 1C), time (30min) and pH (7.4). The reaction solvent of MeOH
and 0.1M PBS was found to play a major role in the RCY with a
concentration of 20% MeOH resulting in the highest yields. The
minimum amount of PS-ODN for quantitative alkylation under
these conditions was evaluated (see Fig. 3), achieving
incorporation 490% with 200mg (31nmol) in a 250mL reaction
volume. The improved labelling conditions appear to be generally
applicable to bromoacetamide alkylation of PS-ODN since0
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Fig. 3. PS-ODN concentration-dependent incorporation of [18F]FPyBrA.we obtained similar yields using [18F]FBBA to produce [18F]FBBA-
PS-ODN (data not shown).
Reverse phase HPLC is an effective tool for analysis and
puriﬁcation of the labelled and unlabelled ODN as shown in Fig. 4.
[18F]FPyBrA-PS-ODN eluted from the column with a shift of
1min in comparison with unlabelled PS-ODN (Fig. 4A,C),
whereas free [18F]FPyBrA eluted with a shift of 410min (Fig. 4B).
The integrity of the PS-ODN was conﬁrmed by HPLC analysis of the
radiolabelling mixture coinjected with unlabelled PS-ODN
(Fig. 4D). The recovery of the HPLC system was 99% and the
formation of radiocolloids (as determined by solid phase
extraction) was o2%. The virtually quantitative yield obtained in
the coupling reaction found in this study raises the possibility of
using the labelled ODN products without employing HPLC
puriﬁcation, either directly from the synthesis or by a straight-
forward solid phase extraction method to remove minor impurities
or incompatible solvents. For many imaging applications of
radiolabelled ODN very high speciﬁc activities will be required. In
our preliminary labelling studies we used up to 170MBq
[18F]FPyBrA, achieving a maximum speciﬁc activity of 5–6GBq/
mmol. This speciﬁc activity could be increased by: (a) higher
starting activities of 18F, (b) ﬁnding reaction conditions requiring
reduced starting ODN amount and (c) separation of labelled and
unlabelled ODN. In general the isolation of labelled ODN from the
bulk of unlabelled material is not possible due to the small change
in physiochemical properties following labelling. In the present
study the 1min shift in HPLC retention time for the [18F]FPyBrA-
PS-ODN relative to the unlabelled ODN should allow the isolation
of a very high speciﬁc activity product.4. Conclusion
By the application of modular automated chemistry [18F]FPy-
BrA can be obtained within 65min in overall decay-corrected
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[18F]FPyBrA in a remotely controlled synthesis unit allows the
convenient preparation of sufﬁcient amounts of [18F]FPyBrA for
labelling PS-ODN and other thiol group containing biomolecules.
The very high yield conjugation of [18F]FPyBrA to ODN provides
the radiolabelled probe in a short synthesis time and at relatively
high speciﬁc activity. To our knowledge this is the ﬁrst report on
almost quantitative 18F-labelling of an ODN using prosthetic group
coupling chemistry. The high overall yield in the coupling reaction
and the potential for rapid puriﬁcation without chromatographic
isolation of the labelled ODN presents an overall beneﬁt for the
application of ODN in preclinical studies and potential clinical
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